²é¿´: 6117  |  »Ø¸´: 3

enantiomer

¾èÖú¹ó±ö (ÕýʽдÊÖ)

[ÇóÖú] ÇóÖúÑ¡ÔñÐÔHDAC3ÒÖÖÆ¼ÁRGFP966Ñо¿½øÕ¹ ÒÑÓÐ1È˲ÎÓë

ÍòÄܳæ×ÓÃÇ£¬ÄÄλÈÊÐÖÖªµÀHDAC3Ñ¡ÔñÐÔÒÖÖÆ¼ÁRGFP966£¨CAS£º1357389-11-7 £©µÄ×îÐÂÑо¿½øÕ¹¡£
Ò»Ö±Ïë¿´¿´Õâ¸ö»¯ºÏÎïµÄÑо¿½øÕ¹£¬µ«ÊÇ´Ó2012ÄêÉêÇëרÀûÒÔÀ´£¬ºÃÏñû¿´µ½ÓÐʲôÁÙ´²Ñо¿½øÕ¹·½ÃæµÄ±¨µÀ¡£ÓÐÖªÇéÕß·³ÇëÌáʾһ¶þ¡£

ÇóÖúÑ¡ÔñÐÔHDAC3ÒÖÖÆ¼ÁRGFP966Ñо¿½øÕ¹
RGFP966.gif.png
»Ø¸´´ËÂ¥
Still water runs deep!
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

enantiomer

¾èÖú¹ó±ö (ÕýʽдÊÖ)

ºÃÉËÐİ¡£¬¾ÓȻûÓÐÈË»ØÎÒ¡£Èç¹ûÓгæÓÑÖªµÀÕâ¸ö»¯ºÏÎïÒѾ­Í£Ö¹¿ª·¢ÁË£¬ÄÜ·ñ¸æËßÊÇÒòΪʲôԭÒòÍ£Ö¹£¬ÓÐûÓй¹Ð§¹ØÏµÒ»ÀàµÄÎÄÏס£Ð»Ð»£¡
Still water runs deep!
2Â¥2017-12-15 12:45:55
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

jxybin

ľ³æ (СÓÐÃûÆø)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
enantiomer(ÁèÓîÀ׳شú·¢): ½ð±Ò+10, ¹ÄÀø»ý¼«²ÎÓë»ØÌûÓ¦Öú\(^o^)/~ 2018-09-30 08:25:36
²»ÖªµÀÕâ¸öÄܲ»ÄܰﵽÄã
https://onlinelibrary.wiley.com/doi/full/10.1002/cmdc.201700157
ÀïÃæÌáµ½The compound showed good PK/PD relationship and good exposure time in phase 1b clinical trials, and it is now in the planning stages for phase 2b trials.
ÁíÍâÒ»¸ö±È½ÏÐÂÒ»µãµÄ±¨µÀ
https://www.tandfonline.com/doi/abs/10.1080/13543776.2017.1262350
ÀïÃæÌáµ½however, in the 700 mg dose group reversible transaminase elevations were observed in four patients, which prompted the company to cancel testing VTP-43742 at a initially planned third, higher dose. In Vitae Pharmaceuticals latest patent applications, WO2016061160 and US20160122345, potential dihydropyrrolopyridine back-up compounds of clinical candidate VTP-43742 (covered in WO2015116904) are disclosed.
»¹Óдý¿¼Ö¤°É
3Â¥2018-03-21 10:28:58
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

enantiomer

¾èÖú¹ó±ö (ÕýʽдÊÖ)

ÒýÓûØÌû:
3Â¥: Originally posted by jxybin at 2018-03-21 10:28:58
²»ÖªµÀÕâ¸öÄܲ»ÄܰﵽÄã
https://onlinelibrary.wiley.com/doi/full/10.1002/cmdc.201700157
ÀïÃæÌáµ½The compound showed good PK/PD relationship and good exposure time in phase 1b clinical trials,  ...

ºÜÓÐÓõģ¬Ð»Ð»Äú£¡ºÃ¾ÃûÀ´Ð¡Ä¾³æÁË£¬Ã»Óм°Ê±»Ø¸´Äú£¬¶Ô²»ÆðÁË£¡
Still water runs deep!
4Â¥2018-09-11 15:24:08
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ enantiomer µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 085601Çóµ÷¼Á×Ü·Ö293Ó¢Ò»Êý¶þ +3 ¸ÖÌú´óÅÚ 2026-03-24 3/150 2026-03-24 22:03 by bingxueer79
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤¿¼Ñе÷¼Á +7 ‹üÈA 2026-03-22 7/350 2026-03-24 21:04 by greychen00
[¿¼ÑÐ] 0856²ÄÁÏר˶353Çóµ÷¼Á +6 NIFFFfff 2026-03-20 6/300 2026-03-24 21:02 by helloÆßÆß
[¿¼ÑÐ] Çóµ÷¼Á +5 ÁÖ֮Ϧ 2026-03-24 5/250 2026-03-24 17:16 by dick_runner
[¿¼ÑÐ] Çóµ÷¼Á +6 ÑÐÑУ¬½Óµç»° 2026-03-24 7/350 2026-03-24 17:01 by barlinike
[¿¼ÑÐ] 080500Çóµ÷¼Á +3 zzzzfan 2026-03-24 3/150 2026-03-24 16:38 by barlinike
[¿¼ÑÐ] Ò»Ö¾Ô¸211 ³õÊÔ270·Ö Çóµ÷¼Á +5 ¹ÈÓêÉϰ¶ 2026-03-23 6/300 2026-03-24 16:32 by laoshidan
[¿¼ÑÐ] 279·ÖÇóµ÷¼Á Ò»Ö¾Ô¸211 +18 chaojifeixia 2026-03-19 20/1000 2026-03-24 10:34 by dolphin_ycj
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ª´ó»¯Ñ§322Çóµ÷¼Á +4 17501029541 2026-03-23 6/300 2026-03-24 10:21 by ´÷Χ²±µÄСÎÃ×Ó
[¿¼ÑÐ] 335Çóµ÷¼Á +4 yuyuÓî 2026-03-23 5/250 2026-03-23 23:49 by Txy@872106
[¿¼ÑÐ] 291 Çóµ÷¼Á +4 »¯¹¤2026½ì±ÏÒµÉ 2026-03-21 5/250 2026-03-23 16:46 by »¯¹¤2026½ì±ÏÒµÉ
[¿¼ÑÐ] ±±¿Æ281ѧ˶²ÄÁÏÇóµ÷¼Á +8 tcxiaoxx 2026-03-20 9/450 2026-03-23 12:16 by tcxiaoxx
[¿¼ÑÐ] 276Çóµ÷¼Á +3 YNRYG 2026-03-21 4/200 2026-03-23 08:31 by ×íÔÚ·çÀï
[¿¼ÑÐ] 293Çóµ÷¼Á +3 ÌÎÌÎWjt 2026-03-22 5/250 2026-03-22 22:21 by jiangpengfei
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖÐÄÏ»¯Ñ§£¨0703£©×Ü·Ö337Çóµ÷¼Á +9 niko- 2026-03-19 10/500 2026-03-22 16:08 by ColorlessPI
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ071000£¬Çóµ÷¼Á +4 ÑØ°¶Óб´¿Ç6 2026-03-21 4/200 2026-03-22 07:21 by ilovexiaobin
[¿¼ÑÐ] Ò»Ö¾Ô¸¶«»ª´óѧ¿ØÖÆÑ§Ë¶320Çóµ÷¼Á +3 Grand777 2026-03-21 3/150 2026-03-21 19:23 by ¼òÖ®-
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤£¨0856£©304ÇóBÇøµ÷¼Á +3 Çñgl 2026-03-20 7/350 2026-03-21 19:05 by 15709483992
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖØÇì´óѧ085700×ÊÔ´Óë»·¾³×Ü·Ö308Çóµ÷¼Á +7 īīĮ 2026-03-20 7/350 2026-03-21 16:36 by barlinike
[¿¼ÑÐ] 085601µ÷¼Á 358·Ö +3 zzzzggh 2026-03-20 4/200 2026-03-21 10:21 by luoyongfeng
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û